View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsTryp Therapeutics 過去の業績過去 基準チェック /06Tryp Therapeutics は平均年間 4.9% の収益成長を遂げていますが、Pharmaceuticals 業界では年間 収益成長率 となっています。9.4% です。主要情報4.94%収益成長率56.35%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報29 Feb 2024最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 05Tryp Therapeutics to be Delisted from the Canadian Securities Exchange and to Stop Trading on the OTCQB Venture Market Following the ArrangementTryp Therapeutics Inc. has been acquired by Exopharm Limited through an all-stock transaction, as the plan of arrangement has been finalized, allowing Tryp shareholders to exchange each of their shares for 3.616 Exopharm shares. Following the arrangement, Tryp will be delisted from the Canadian Securities Exchange and will stop trading on the OTCQB Venture Market. Exopharm shares are set to begin trading on the Australian Securities Exchange under the new name ‘Tryptamine Therapeutics Limited’ with the ticker ‘TYP’.お知らせ • May 03Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction.Tryp Therapeutics Inc. (CNSX:TRYP) entered into a definitive agreement to acquire Exopharm Limited (ASX:EX1) for CAD 7.2 million in a reverse merger transaction on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering. As of January 25, 2024, Tryp entered into an amendment to its arrangement agreement with Exopharm Limited. Under the revised terms, Exopharm will acquire all issued and outstanding common shares of Tryp, in exchange for 3.616 ordinary shares of Exopharm for each Tryp share, a change from the previously stated ratio of 4.52. Additionally, there will be a consolidation of Exopharm shares before completing the transaction, adjusting from a 2:1 to a 2.5:1 consolidation ratio.The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement, Exopharm Capital Raise. Tryp will pay termination fee of CAD 1 million while Exopharm shall pay CAD 0.2 million. Post acquisition, Exopharm will change its name to Tryptamine Therapeutics Australia Limited and the symbol TYP. As of March 8, 2024 Exopharm and Tryp Therapeutics Inc signed a Binding Arrangement Agreement. Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Alan Hutchison of Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements. Computershare Investor Services Inc. acted as a transfer agent of Tryp while Automic Pty Ltd. acted as a transfer agent of Exopharm.Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction on May 1, 2024.お知らせ • Feb 11Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder MeetingTryp Therapeutics Inc. announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim Order") of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991 to be implemented under a statutory plan of arrangement pursuant to section 288 of the Business Corporations Act (British Columbia). The Interim Order provides for the holding of an annual general and special meeting of Tryp securityholders to, among other things, consider and vote on a special resolution approving the Arrangement.お知らせ • Dec 16Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024.お知らせ • Dec 12Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million.Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering. The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement. Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements.お知らせ • Nov 21Tryp Therapeutics Inc. announced that it has received AUD 3.215 million in fundingOn November 20, 2023, Tryp Therapeutics Inc. closed the transaction. The company issued AUD 3.215 million in the transaction. Closing of the Private Placement is subject to final approval by the Canadian Securities Exchange. The securities issued in the Private Placement, including the common shares issuable on conversion of the Notes, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws. The transaction included participation from new investor Jason Carroll for AUD 0.325 million. The company will pay 6% of proceeds raised under the Private Placement and will be issued such number of warrants as equals to 4.0% of the Common Shares issuable on conversion of the Notes. The transaction was oversubscribed.お知らせ • Oct 12Tryp Therapeutics Inc. announced that it has received AUD 0.175 million in fundingOn October 11, 2023, Tryp Therapeutics Inc. closed the transaction.お知らせ • Oct 05Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in fundingTryp Therapeutics Inc. announced a private placement of unsecured convertible debentures for gross proceeds of up to AUD 175,000 on October 4, 2023. The debentures will have a term of 12 months and will be interest free. The debentures shall automatically convert into common shares in the capital of the company on the earlier of the maturity date or the time the company is completing a liquidity event. The price at which the debentures will be converted into common shares will vary depending on various scenarios as set out in the debenture and at a conversion price fixed in accordance with CSE policies. Closing of the private placement is anticipated to occur on or about October 11, 2023, and is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the Canadian Securities Exchange. The Debentures and the underlying common shares will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.お知らせ • Aug 04Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023Tryp Therapeutics Inc. announced the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023. Mr. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb.お知らせ • Aug 03Tryp Therapeutics Inc. Announces the Passing of David Tousley, DirectorTryp Therapeutics Inc. announced the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Board with consistent, sage advice. His input was always well-reasoned and practical on issues brought to the Board. He worked tirelessly on behalf of TRYP and was always available for discussions on many detailed matters.お知らせ • May 25Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General HospitalTryp Therapeutics Inc. announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS) at Massachusetts General Hospital (MGH). The planned open label study in collaboration with Harvard Medical School/Mass Massachusetts General Hospital will evaluate the effect of psilocybin- assisted psychotherapy in patients with treatment-resistant IBS who experience chronic abdominal pain and other debilitating gastrointestinal symptoms. Many of these patients also suffer from fibromyalgia, anxiety and fatigue. The primary efficacy endpoint of the study will be improvement in abdominal pain. The proposed study will also explore changes in brain connectivity and responses to pain at baseline and at four weeks, six months and twelve months post the psychedelic drug sessions, along with numerous other secondary endpoints.お知らせ • Jan 06Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder with Psilocybin-Assisted PsychotherapyTryp Therapeutics Inc. announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida, the STOP trial is evaluating TRP-8802 (oral psilocybin) in patients with binge eating disorder ("BED") and represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. Previously, Tryp reported that immediately following the post-dosing integration session with the trial's psychotherapists and throughout the four-week period post-dosing, the first patient in the STOP trial exhibited reduced overall anxiety, reduced anxiety around food, reduced compulsion to overeat and improved self-image and confidence. Analysis of the additional four patients has reinforced the initial clinical observations. The current results demonstrated a significant reduction in the frequency of binge eating behavior for each patient as measured in multiple assessments of efficacy which were discussed with the FDA as acceptable endpoints in advance of this study. In addition, analysis of the Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores demonstrated improving trends related to patients' levels of anxiety and depression. The observed behavioral improvements are consistent with those described in other clinical studies examining the clinical benefit of psilocybin as a therapeutic intervention in compulsion-related disorders. There were no drug-related adverse events reported by these patients during the four-week period following dosing of TRP-8802. Tryp Therapeutics will be presenting at Biotech Showcase in San Francisco at 11am PT on Monday, January 9, and the presentation will include a review of this interim data.収支内訳Tryp Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:TRYP.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費29 Feb 240-32-130 Nov 230-52231 Aug 230-52231 May 230-62428 Feb 230-62430 Nov 220-63331 Aug 220-74331 May 220-86228 Feb 220-108230 Nov 210-118231 Aug 210-86131 May 210-650質の高い収益: TRYP.Fは現在利益が出ていません。利益率の向上: TRYP.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TRYP.Fは利益を出していないが、過去 5 年間で年間4.9%の割合で損失を削減してきた。成長の加速: TRYP.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: TRYP.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: TRYP.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/02 04:25終値2024/05/02 00:00収益2024/02/29年間収益2023/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Entropy Neurodynamics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael HigginsLadenburg Thalmann & Company
お知らせ • May 05Tryp Therapeutics to be Delisted from the Canadian Securities Exchange and to Stop Trading on the OTCQB Venture Market Following the ArrangementTryp Therapeutics Inc. has been acquired by Exopharm Limited through an all-stock transaction, as the plan of arrangement has been finalized, allowing Tryp shareholders to exchange each of their shares for 3.616 Exopharm shares. Following the arrangement, Tryp will be delisted from the Canadian Securities Exchange and will stop trading on the OTCQB Venture Market. Exopharm shares are set to begin trading on the Australian Securities Exchange under the new name ‘Tryptamine Therapeutics Limited’ with the ticker ‘TYP’.
お知らせ • May 03Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction.Tryp Therapeutics Inc. (CNSX:TRYP) entered into a definitive agreement to acquire Exopharm Limited (ASX:EX1) for CAD 7.2 million in a reverse merger transaction on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering. As of January 25, 2024, Tryp entered into an amendment to its arrangement agreement with Exopharm Limited. Under the revised terms, Exopharm will acquire all issued and outstanding common shares of Tryp, in exchange for 3.616 ordinary shares of Exopharm for each Tryp share, a change from the previously stated ratio of 4.52. Additionally, there will be a consolidation of Exopharm shares before completing the transaction, adjusting from a 2:1 to a 2.5:1 consolidation ratio.The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement, Exopharm Capital Raise. Tryp will pay termination fee of CAD 1 million while Exopharm shall pay CAD 0.2 million. Post acquisition, Exopharm will change its name to Tryptamine Therapeutics Australia Limited and the symbol TYP. As of March 8, 2024 Exopharm and Tryp Therapeutics Inc signed a Binding Arrangement Agreement. Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Alan Hutchison of Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements. Computershare Investor Services Inc. acted as a transfer agent of Tryp while Automic Pty Ltd. acted as a transfer agent of Exopharm.Tryp Therapeutics Inc. (CNSX:TRYP) completed the acquisition of Exopharm Limited (ASX:EX1) in a reverse merger transaction on May 1, 2024.
お知らせ • Feb 11Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder MeetingTryp Therapeutics Inc. announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim Order") of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991 to be implemented under a statutory plan of arrangement pursuant to section 288 of the Business Corporations Act (British Columbia). The Interim Order provides for the holding of an annual general and special meeting of Tryp securityholders to, among other things, consider and vote on a special resolution approving the Arrangement.
お知らせ • Dec 16Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024Tryp Therapeutics Inc., Annual General Meeting, Feb 16, 2024.
お知らせ • Dec 12Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million.Exopharm Limited (ASX:EX1) entered into a definitive agreement to acquire Tryp Therapeutics Inc. (CNSX:TRYP) for CAD 7.2 million on December 8, 2023. Pursuant to the agreement Exopharm has agreed to acquire all of the issued and outstanding common shares in the capital of Tryp (the “Tryp Shares”) in consideration of the issuance of 4.52 ordinary shares in the capital of Exopharm (the “Exopharm Shares”) for each one (1) Tryp Share. Pursuant to the arrangement agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes (collectively, the “Tryp Convertible Securities”) will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX. The purchase price of CAD 0.08 per Tryp Share and aggregate transaction value of approximately CAD 12.8 million. The majority of the directors of the combined entity to be appointed by Tryp. The combined entity is expected to relist on the Australian Securities Exchange (the “ASX”) in Q1 2024 subject to, among other conditions, receipt of the requisite approval of Exopharm shareholders and raising a minimum of AUD 6,000,000 under a public offering. The Arrangement is subject to customary closing conditions, including approvals from Tryp securityholders and Exopharm shareholders, all other applicable third party, regulatory consents for the Arrangement, no more than 10% of the Company's shareholders exercising their rights of dissent in connection with the Arrangement, approvals from the ASX and the Supreme Court of British Columbia (the “Court”). Both the Board and the Special Committee unanimously recommend that Tryp securityholders vote in favor of the Arrangement. Pushor Mitchell LLP acted as legal counsel to Tryp in Canada and K&L Gates LLP acted as legal counsel to Tryp in Australia in connection with the Arrangement. Osler, Hoskin & Harcourt LLP acted as legal counsel to Exopharm in Canada and Hamilton Locke Pty Ltd acted as legal counsel to Exopharm in Australia. ACNS Capital Markets Pty Ltd trading as Alto Capital acted as Exopharm’s corporate advisor in connection with the arrangements.
お知らせ • Nov 21Tryp Therapeutics Inc. announced that it has received AUD 3.215 million in fundingOn November 20, 2023, Tryp Therapeutics Inc. closed the transaction. The company issued AUD 3.215 million in the transaction. Closing of the Private Placement is subject to final approval by the Canadian Securities Exchange. The securities issued in the Private Placement, including the common shares issuable on conversion of the Notes, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws. The transaction included participation from new investor Jason Carroll for AUD 0.325 million. The company will pay 6% of proceeds raised under the Private Placement and will be issued such number of warrants as equals to 4.0% of the Common Shares issuable on conversion of the Notes. The transaction was oversubscribed.
お知らせ • Oct 12Tryp Therapeutics Inc. announced that it has received AUD 0.175 million in fundingOn October 11, 2023, Tryp Therapeutics Inc. closed the transaction.
お知らせ • Oct 05Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in fundingTryp Therapeutics Inc. announced a private placement of unsecured convertible debentures for gross proceeds of up to AUD 175,000 on October 4, 2023. The debentures will have a term of 12 months and will be interest free. The debentures shall automatically convert into common shares in the capital of the company on the earlier of the maturity date or the time the company is completing a liquidity event. The price at which the debentures will be converted into common shares will vary depending on various scenarios as set out in the debenture and at a conversion price fixed in accordance with CSE policies. Closing of the private placement is anticipated to occur on or about October 11, 2023, and is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the Canadian Securities Exchange. The Debentures and the underlying common shares will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
お知らせ • Aug 04Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023Tryp Therapeutics Inc. announced the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023. Mr. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb.
お知らせ • Aug 03Tryp Therapeutics Inc. Announces the Passing of David Tousley, DirectorTryp Therapeutics Inc. announced the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Board with consistent, sage advice. His input was always well-reasoned and practical on issues brought to the Board. He worked tirelessly on behalf of TRYP and was always available for discussions on many detailed matters.
お知らせ • May 25Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General HospitalTryp Therapeutics Inc. announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS) at Massachusetts General Hospital (MGH). The planned open label study in collaboration with Harvard Medical School/Mass Massachusetts General Hospital will evaluate the effect of psilocybin- assisted psychotherapy in patients with treatment-resistant IBS who experience chronic abdominal pain and other debilitating gastrointestinal symptoms. Many of these patients also suffer from fibromyalgia, anxiety and fatigue. The primary efficacy endpoint of the study will be improvement in abdominal pain. The proposed study will also explore changes in brain connectivity and responses to pain at baseline and at four weeks, six months and twelve months post the psychedelic drug sessions, along with numerous other secondary endpoints.
お知らせ • Jan 06Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder with Psilocybin-Assisted PsychotherapyTryp Therapeutics Inc. announced interim results for the first five patients dosed in its Phase II STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida, the STOP trial is evaluating TRP-8802 (oral psilocybin) in patients with binge eating disorder ("BED") and represents the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. Previously, Tryp reported that immediately following the post-dosing integration session with the trial's psychotherapists and throughout the four-week period post-dosing, the first patient in the STOP trial exhibited reduced overall anxiety, reduced anxiety around food, reduced compulsion to overeat and improved self-image and confidence. Analysis of the additional four patients has reinforced the initial clinical observations. The current results demonstrated a significant reduction in the frequency of binge eating behavior for each patient as measured in multiple assessments of efficacy which were discussed with the FDA as acceptable endpoints in advance of this study. In addition, analysis of the Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores demonstrated improving trends related to patients' levels of anxiety and depression. The observed behavioral improvements are consistent with those described in other clinical studies examining the clinical benefit of psilocybin as a therapeutic intervention in compulsion-related disorders. There were no drug-related adverse events reported by these patients during the four-week period following dosing of TRP-8802. Tryp Therapeutics will be presenting at Biotech Showcase in San Francisco at 11am PT on Monday, January 9, and the presentation will include a review of this interim data.